The U.S. Food and Drug Administration (FDA) and Novartis have reached an agreement to allow the Swiss pharmaceutical company to proceed with a clinical trial of hydroxychloroquine for patients with COVID-19, the disease caused by the novel coronavirus.
Trending:
FDA allows Novartis to test hydroxychloroquine against COVID-19